B A S E C A R E
He Yunshao from Da An gene: The industrial layout 26 years ago laid a solid foundation for the global leading position of domestic viral nucleic acid reagents
25th Sep 2020 · Suzhou
Recently, general secretary Xi Jinping's important speech at the forum of scientists directed the direction of technological development. He Yunshao, chairman of Da An Gene Co.,Ltd. Of Sun Yat-Sen university (hereinafter referred to as Da An Gene), was one of the representatives of entrepreneurs.

Recently, general secretary Xi Jinping's important speech at the forum of scientists directed the direction of technological development. He Yunshao, chairman of Da An Gene Co.,Ltd. Of Sun Yat-Sen university (hereinafter referred to as Da An Gene), was one of the representatives of entrepreneurs.

As a leading enterprise in the field of molecular diagnostic segmentation, Da An Gene is also a strategic investor of Suzhou Basecare Medical Co., Ltd. (hereinafter referred to as "Basecare").

Da An Gene has been working hard to fight for the global outbreak of Coronavirus pandemic. After obtaining the gene sequence data of the new coronavirus, it organized R&D quickly to develop the coronavirus (2019) nucleic acid detection kit (PCR- fluorescence probe method) as soon as possible, this product is universal with routine nucleic acid testing laboratory, and can complete the whole detection process within 30 minutes as soon as possible. It can be widely used in clinical, CDC and customs inspection and quarantine. The daily output of the product is about 1 million people, which will provide strong technical support for epidemic prevention and control.


Basecare is a leading enterprise in the reproductive field of NGS market invested by Da An gene. The company has been strongly supported by Da An gene in the development process, and has been adhering to the concept of "doing compliance products" since its establishment. The PGT-A kit independently developed by Basecare was publicized by medical device technology evaluation center of CFDA in may 2016, becoming the first PGT-A product to obtain “special approval for innovative medical devices”.This test kit also obtained the first Class-III  medical device registration certificate in the industry earlier this year (Approval No.20203400181). This success marks the beginning of a new era, in which China’s preimplantation genetic testing technology is licensed and under official supervision. In the future, Basecare will continue the business pace of Da An gene, focus on the product research and development and innovation of gene technology in the field of reproductive field, develop more competitive products and services, and step forward to become an international brand in the field of reproductive health.